therapeutic areas
-
Rare and orphan diseases: hemophilia, hereditary angioedema, Fabry, Gaucher, CLL, pulmonary hypertension, hereditary hyper-cholesterolemia, multiple scleroses, Pompe, etc.
-
Oncology products (traditional and biologic)
-
Rheumatoid arthritis, Lupus, Psoriatic arthritis (traditional and biologic)
-
Anti-infective/Anti-viral agents (Anthelmintics, Antibacterial agents, Antibiotics, Antimicotics, HIV, etc.)
-
Immunosuppressive agents
-
Antidiabetic agents (oral, injectables, insulins, full coverage)
-
Antihistamines
-
Anticoagulants, platelet aggregation inhibitors, thrombolytic agents, etc.
-
Vaccines
-
Nuclear medicine
-
Contraceptives (Contraceptives, intracervical devices, intrauterine devices, intravaginal, sub-dermal implant)
-
Bronchodilators
-
Bone diseases (osteoporoses, etc.)
-
Cardiovascular drugs (Angiotensin converting enzyme inhibitors, Calcium antagonists, Hypotensive agents, Vasodilating agents, etc)
-
Central nervous system drugs (Analgesics, Anticonvulsants, Antidepressants, Central nervous system depressants, Anxiolytics, Antimanic agents, Alzheimer products, Multiple scleroses, etc.)
-
Corticoids
-
Dermatology products, psoriasis
-
Gastrointestinal drugs (Antacids, Antidiarrhea agents, Cathartics and laxatives, Anti-emetics)
-
Hormones (Androgens, Contraceptives, Estrogens, Estrogens conjugated, Gonadotropins)
-
Nutrotherapic products
-
Dietary supplements (adults, pediatrics)
-
Infant milk formulas
-
Ophthalmic (monoclonal, etc.)
-
Pain management
-
Sexual dysfunction
-
Vitamins
case studies
Rare diseases: Hereditary Angioedema
Challenge
-
Situation diagnosis for the Hereditary Angioedema market in Argentina: Incidence, Treatment and Up-take of the new product. Treatment costs. Approval circuit within institutions. Incorporation circuit of new product within PAMI, IOMA and Pre-paid Healthcare System
Actions
-
Exploratory qualitative study, interviewing specialists (allergies and immunology) and auditors within target institutions.
Result
-
Able to plan actions to access target institutions based on the positioning of the new product according to cost-benefit assessment in crisis prevention.
Rare Disease: Chronic immune deficiency
Challenge
-
Situation diagnosis for the Chronic immune deficiency market: patient workload, referral circuit, diagnosis and indications, brand positioning
Actions
-
Exploratory qualitative study, interviewing Hematologists, Immunologists and Neurologists.
Result
-
Able to identify specific indications treated with gamma globulin by different specialists and patient workloads; competitive capacity of the product within the market.
Rare Disease: Hemophilia
Challenge
-
Identification of business opportunities within the Hemophilia market: market sizing, patient flow and treatment pathway. Coverage and access to treatment.
Actions
-
Qualitative study with quantitative validation, interviewing hematologists – KOL’s, High Prescribers, auditing Doctors. Type A Hemophilia patients and caregivers.
Result
-
Able to evaluate with precision the sales potential of the product during the different stages of the disease. Also able to size the strategic opportunity for secondary prevention.